Symbio Pharmaceuticals Limited (4582) AI Stock Analysis

• Market Cap: ¥7.33B
• Dividend Yield: N/A
• Average Volume (3M): 339.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: -50.88%
• EPS Growth: -22.14%
• Country: JP
• Employees: 108
• Sector: Healthcare
• Sector Strength: 51
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -21.40
• Shares Outstanding: 49,615,456
• 10 Day Avg. Volume: 311,720
• 30 Day Avg. Volume: 339,640
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: ―

Symbio Pharmaceuticals is currently facing significant financial challenges with declining revenues and negative profitability. A strong equity position without debt provides some stability, but the company must focus on improving revenue and managing costs. Technical analysis shows mixed signals, with slight momentum concerns. Valuation remains a concern due to negative earnings and lack of dividends, making the stock an unattractive option for income investors.

Symbio Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

How the Company Makes Money

Symbio Pharmaceuticals Limited generates revenue through multiple streams, primarily by manufacturing and selling pharmaceutical products. The company's core revenue comes from the sale of its proprietary prescription drugs and over-the-counter medications to healthcare providers, pharmacies, and direct consumers. Symbio also engages in licensing agreements and strategic partnerships with other pharmaceutical companies, leveraging its research and development capabilities to co-develop new medications and treatments. Additionally, the company may receive milestone payments and royalties from these partnerships, further contributing to its income. By consistently investing in research and development, Symbio Pharmaceuticals ensures a steady pipeline of innovative products that drive its growth and profitability.

Symbio Pharmaceuticals Limited Financial Statement Overview

Summary

Symbio Pharmaceuticals is navigating a challenging period with declining revenues and significant losses impacting profitability and cash flow. The company maintains a strong equity position with no debt, which could support future recovery. However, strategic improvements in revenue generation and cost management are essential for financial stability.

Income Statement

Symbio Pharmaceuticals has faced significant challenges, with revenues declining from 2022 to 2024. The company has been operating at a loss with negative EBIT and EBITDA margins, and a substantial decrease in net income. The gross profit margin remains reasonable, but overall profitability is severely impacted by high operating losses.

Balance Sheet

The company maintains a strong equity position with no debt, reflected in a debt-to-equity ratio of zero. However, the return on equity has been negative due to sustained net losses. The equity ratio is healthy, indicating a solid capital structure despite financial losses.

Cash Flow

Symbio Pharmaceuticals has experienced negative free cash flow growth, consistent with operating losses. Operating cash flow has been negative, indicating cash flow challenges. Free cash flow to net income ratios are also negative, highlighting the need for cash management improvements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.12B	2.45B	5.59B	10.01B	8.25B	2.99B
Gross Profit	1.60B	1.87B	4.41B	7.60B	5.80B	866.85M
EBITDA	-4.50B	-3.78B	-714.00M	2.20B	1.11B	-4.44B
Net Income	-4.38B	-3.83B	-1.96B	1.18B	2.03B	-4.09B
Balance Sheet
Total Assets	4.67B	4.97B	8.17B	10.43B	8.45B	6.27B
Cash, Cash Equivalents and Short-Term Investments	3.61B	3.96B	6.52B	6.28B	3.86B	3.85B
Total Debt	700.00M	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.27B	770.77M	960.33M	1.93B	1.71B	1.62B
Stockholders Equity	3.40B	4.20B	7.21B	8.51B	6.75B	4.66B
Cash Flow
Free Cash Flow	0.00	-3.44B	-427.48M	1.57B	76.20M	-4.27B
Operating Cash Flow	0.00	-3.42B	-194.69M	1.61B	140.04M	-4.12B
Investing Cash Flow	0.00	-3.96M	-376.70M	-47.13M	-70.85M	-160.31M
Financing Cash Flow	0.00	708.47M	680.16M	627.99M	-71.92M	4.22B

Symbio Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 146.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Negative. The current price of 146 is below the 20-day moving average (MA) of 151.30, below the 50-day MA of 160.08, and below the 200-day MA of 177.79, indicating a bearish trend. The MACD of -3.65 indicates Positive momentum. The RSI at 35.04 is Neutral, neither overbought nor oversold. The STOCH value of 23.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4582.

Symbio Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4524	78 Outperform	¥9.03B	19.49		2.49%	-0.09%	-29.95%
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%
4582	51 Neutral	¥7.33B	―		―	-50.88%	-22.14%
9SO	―	€55.29M	―	-122.54%	―	―	―
4892	44 Neutral	¥5.72B	―		―	8.12%	-19.12%
4586	41 Neutral	¥6.23B	―		―	-82.19%	-106.15%
4883	39 Underperform	¥7.05B	―		―	―	64.87%

Symbio Pharmaceuticals Limited Corporate Events

SymBio Pharmaceuticals Reports Significant Financial Decline in FY 2024

SymBio Pharmaceuticals Limited reported a significant decline in financial performance for the fiscal year 2024, with net sales falling by 56.1% and a substantial increase in net loss compared to the previous year. The company continues to face challenges, including a decrease in total assets and cash equivalents, while planning a new subsidiary in the USA, which may impact its future operations and market positioning.